



Clinical Edit Criteria Proposal

Drug/Drug Class Date: Prepared for: Prepared by:	March 31, 2005 epared for:			
New Criteria	a	Revision of Existing Criteria		
Executive Sum	nmary			
Purpose:	Monitor the use of Miralax Powder for Oral Solution as first line treatmen of constipation.			
Why was this Issue Selected:	Miralax prescription claims are significantly more expensive to the pharmacy program than other drugs prescribed for constipation. The average Miralax prescription costs the program \$35.42. The average prescription claim for non-prescription laxatives costs the program \$9.16.			
Program- specific information:	 Drug Miralax Powder Docusate 100mg Caps Dulcolax 5mg Tabs Senokot-S Tabs 	Claims 35,126 16,534 2,731 3,212	Expense \$1,244,181 \$144,948 \$23,080 \$37,975	
Setting & Population:	Patients 13 years of age and of	der		
Type of Criteria:	☐ Increased risk of ADE	⊠ Non-Pref	⊠ Non-Preferred Agent	
	⊠ Effectiveness	☐ Other:	☐ Other:	
Data Sources:	☐ Only administrative databases	⊠ Database supplied	es + Prescriber-	

Setting & Population

- Drug/drug class for review: Miralax
- Age range: All patients 13 years of age and older
- Gender: males and females

Approval Criteria

- Appropriate diagnosis Constipation
- Trial and failure on at least 2 different covered laxative preparations
- ADE/ADR to covered laxative products
- Contraindication to covered laxative products
- Pediatric patients under 12 years of age with Diagnosis of Constipation
 - Allow short term 90 day approval transparently

Denial Criteria

- No prior prescription claims for covered laxative product in the most recent 45 days
- Lack of ADE/ADR and/or lack of contraindication to covered laxative products
- Lack of appropriate diagnoses

Required Documentation					
Laboratory results: MedWatch form:	Progress notes:				
Disposition of Edit					

• Denial: Edit 682 "Clinical Edit"

References

- 1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2003.
- 2. Facts and Comparisons, pg. 1166-1177; 2004.

